Key facts
- This page summarizes Michael D. Bookman's Form 4 filing for Immuneering Corp (IMRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2026, 08:44.
Michael D. Bookman - 03 Feb 2026 Form 4 Insider Report for Immuneering Corp (IMRX)
- Reporting relationship
- CHIEF LEGAL OFFICER, SECRETARY
- Issuer ticker
- IMRX
- Reported as of
- 03 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2026, 08:44:51 UTC
- Prior SEC filing
- 02 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael D. Bookman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael D. Bookman filed Form 4 for Immuneering Corp (IMRX) on 05 Feb 2026.
Change
- Previous filing in this sequence was filed on 02 Oct 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001840339
Primary reporting owner
Bookman Michael
- Relationship
- CHIEF LEGAL OFFICER, SECRETARY
- Address
- 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
- Signature
- /s/ Michael D. Bookman
- Signature date
- 05 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMRX
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +176,000
- Change %
- Price
- $0.000000
- Shares after
- 176,000
- Date
- 03 Feb 2026
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 176,000
- Exercise price
- $4.91
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.